A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer
The DOI matches its Crossref record.
Abstract
Eighteen patients were treated with escalating doses of recombinant, Escherichia coli-derived human interleukin-6 (IL-6) intravenously every 8 h. Therapy was given for two cycles of 7 days each separated by a week off therapy. Fevers and chills were observed in most patients. Mild renal and liver function abnormalities were noted at higher doses of IL-6. Dose-limiting toxicity was reached at 30 micrograms/kg i.v. every 8 h due to reversible neurotoxicity, but significant rapidly reversible anemia and hyperglycemia were seen at lower doses. Platelet counts, white blood cell counts, and acute phase reactant levels were substantially elevated. No antitumor responses were seen. A maximum tolerated dose of 10 micrograms/kg i.v. every 8 h for two 7-day cycles is recommended for future phase II trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002053 · Cited by 459
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy
Pusztai, L., Mendoza, T. R., Reuben, J. M., Martinez, M. M., Willey, J. S., Lara, J., Syed, A., Fritsche, H. A., Bruera, E., Booser, D., et al. (2004) · Cytokine · doi:10.1016/j.cyto.2003.10.004 · Cited by 312
Mastorakos, G., Weber, J. S., Magiakou, M. A., Gunn, H., & Chrousos, G. P. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.4.7962300 · Cited by 290
Self-citation
Metadata
- Authors
- Weber, J., Gunn, H., Yang, J., Parkinson, D., Topalian, S., Schwartzentruber, D., Ettinghausen, S., Levitt, D., & Rosenberg, S. A.
- Venue
- Journal of Immunotherapy
- Published
- 1994-05
- Volume
- 15
- Issue
- 4
- Pages
- 292-302
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W1964520426
- Cited by
- 59
- References
- 0
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer. https://app.cochat.ai/papers/10.1097/00002371-199405000-00008
- The paper
- Weber, J., Gunn, H., Yang, J., Parkinson, D., Topalian, S., Schwartzentruber, D., Ettinghausen, S., Levitt, D., & Rosenberg, S. A. (1994). A Phase I Trial of Intravenous Interleukin-6 in Patients with Advanced Cancer. Journal of Immunotherapy. https://doi.org/10.1097/00002371-199405000-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.